A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression



Status:Completed
Conditions:Depression, Depression
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 64
Updated:2/23/2019
Start Date:August 10, 2015
End Date:February 20, 2018

Use our guide to learn which trials are right for you!

A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression

The purpose of this study is to compare the efficacy and safety of switching
treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to
which they have not responded) to either intranasal esketamine plus a new oral antidepressant
or switching to a new oral antidepressant plus intranasal placebo.

This is a randomized, double-blind (neither the researchers nor the participants know what
treatment the participant is receiving), active-controlled, multicenter study (more than 1
study site) in participants with TRD to assess the efficacy, safety, and tolerability of
fixed doses of intranasal esketamine plus a newly initiated oral antidepressant compared with
a newly initiated oral antidepressant (active comparator) plus intranasal placebo. The study
will consist of 3 phases: Screening/Prospective Observational Phase (4-7 weeks), Double-blind
Induction Phase (4-weeks), Follow-up Phase (24-weeks). Participants who rollover into a
long-term maintenance study will not participate in the Follow-up Phase. At the start of the
screening/prospective observational phase, the participant must have had documented
non-response to at least 1 antidepressant treatment (based on Massachusetts General Hospital
- Antidepressant Treatment Response Questionnair [MGH-ATRQ]) in the current episode of
depression, and participant is taking a different oral antidepressant treatment on the
MGH-ATRQ for at least the previous 2 weeks at or above the minimum therapeutic dose. This
antidepressant treatment, as well as any other ongoing medications being taken for depression
at screening (including adjunctive/ augmentation therapies), will continue from the start of
Week 1 through the end of Week 4 of the screening/prospective observational phase.
Participants will be randomly assigned to receive Intranasal esketamine (56 milligrams [mg]),
Intranasal esketamine (84 mg), or Intranasal placebo. In addition, each participant will be
assigned to receive 1 of 4 oral antidepressant medications from 2 different classes of
antidepressant treatments, a Selective Serotonin Reuptake Inhibitor (SSRI) (escitalopram or
sertraline) or a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) (duloxetine or
venlafaxine extended release [XR]), initiated on Day 1 and continued through the double-blind
induction phase. Participants will be primarily evaluated for improvement in depressive
symptoms as assessed by change in Montgomery-Asberg Depression Rating Scale (MADRS) total
score at Week 4. Participants' safety will be monitored throughout the study.

Inclusion Criteria:

- At the time of signing the informed consent form (ICF), participant must be a man or
woman 18 (or older if the minimum legal age of consent in the country in which the
study is taking place is greater than [>]18) to 64 years of age, inclusive

- At the start of the screening/prospective observational phase, participant must meet
the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria
for single-episode major depressive disorder (MDD) (if single-episode MDD, the
duration must be greater than or equal to [>=] 2 years) or recurrent MDD, without
psychotic features, based upon clinical assessment and confirmed by the
Mini-International Neuropsychiatric Interview (MINI)

- At the start of the screening/prospective observational phase, participant must have
an Inventory of Depressive Symptomatology-Clinician rated ( IDS-C30) total score of
greater than or equal to (>=) 34

- At the start of the screening/prospective observational phase, participants must have
had non-response (less than or equal to [<=25] percent [%] improvement) to >=1 but
less than or equal to (<=) 5 (if current episode is >2 years, upper limit is
applicable to only the last 2 years) oral antidepressant treatments taken at adequate
dosage and for adequate duration, as assessed using the Massachusetts General Hospital
- Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and documented by medical
history and pharmacy/prescription records, for the current episode of depression.

Participant is taking a different oral antidepressant treatment on the MGH-ATRQ for at
least the previous 2 weeks at or above the minimum therapeutic dose

- The participant's current major depressive episode, depression symptom severity (Week 1
MADRS total score >=28 required), and antidepressant treatment response in the current
depressive episode, must be confirmed using a Site Independent Qualification Assessment

Exclusion Criteria:

- Participants who have previously demonstrated nonresponse of depressive symptoms to
esketamine or ketamine in the current major depressive episode, to all 4 of the oral
antidepressant treatment options available for the double-blind induction phase (i.e,
duloxetine, escitalopram, sertraline, and venlafaxine extended release [XR]) in the
current major depressive episode (based on MGH-ATRQ), or an adequate course of
treatment with electroconvulsive therapy (ECT) in the current major depressive
episode, defined as at least 7 treatments with unilateral/bilateral ECT

- Participant has received vagal nerve stimulation (VNS) or has received deep brain
stimulation (DBS) in the current episode of depression

- Participant has a current or prior DSM-5 diagnosis of a psychotic disorder or MDD with
psychotic features bipolar or related disorders (confirmed by the MINI), obsessive
compulsive disorder (current only), intellectual disability (DSM-5 diagnostic codes
317, 318.0, 318.1, 318.2, 315.8, and 319), autism spectrum disorder, borderline
personality disorder, antisocial personality disorder, histrionic personality
disorder, or narcissistic personality disorder

- Participant has homicidal ideation/intent, per the investigator's clinical judgment,
or has suicidal ideation with some intent to act within 6 months prior to the start of
the screening/prospective observational phase, per the investigator's clinical
judgment or based on the Columbia Suicide Severity Rating Scale (C-SSRS)

- Participants with history of moderate or severe substance or alcohol use disorder
according to DSM-5 criteria
We found this trial at
38
sites
403
mi
from 43215
Media, PA
Click here to add this to my saved trials
4037
mi
from 43215
Aalst,
Click here to add this to my saved trials
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
2001
mi
from 43215
Bothell, WA
Click here to add this to my saved trials
862
mi
from 43215
Bradenton, FL
Click here to add this to my saved trials
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
64
mi
from 43215
Dayton, OH
Click here to add this to my saved trials
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
315
mi
from 43215
Gaithersburg, MD
Click here to add this to my saved trials
1963
mi
from 43215
Garden Grove, CA
Click here to add this to my saved trials
Hoffman Estates, Illinois 60194
301
mi
from 43215
Hoffman Estates, IL
Click here to add this to my saved trials
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
618
mi
from 43215
Lincoln, RI
Click here to add this to my saved trials
622
mi
from 43215
Little Rock, AR
Click here to add this to my saved trials
284
mi
from 43215
Maywood, IL
Click here to add this to my saved trials
993
mi
from 43215
Miami, FL
Click here to add this to my saved trials
398
mi
from 43215
Middleton, WI
Click here to add this to my saved trials
624
mi
from 43215
Minneapolis, MN
Click here to add this to my saved trials
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
419
mi
from 43215
O'Fallon, MO
Click here to add this to my saved trials
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
1959
mi
from 43215
Orange, CA
Click here to add this to my saved trials
792
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
442
mi
from 43215
Quincy, MA
Click here to add this to my saved trials
407
mi
from 43215
Saint Charles, MO
Click here to add this to my saved trials
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
1939
mi
from 43215
San Marcos, CA
Click here to add this to my saved trials
2109
mi
from 43215
San Rafael, CA
Click here to add this to my saved trials
299
mi
from 43215
Schaumburg, IL
Click here to add this to my saved trials
636
mi
from 43215
Watertown, MA
Click here to add this to my saved trials
784
mi
from 43215
Wichita, KS
Click here to add this to my saved trials
596
mi
from 43215
Woodstock, VT
Click here to add this to my saved trials
604
mi
from 43215
Worcester, MA
Click here to add this to my saved trials